Intrinsic resistance to BRAF inhibitors prevents ∼20% of melanoma patients with BRAF-mutant tumors from achieving clinical benefit from this type of target therapy and represents a major clinical issue [31, for review]. The gene discussed is BRAF; the disease is melanoma.